Skip to main content
15039 search results for:

CAR T-Cell Therapy 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-04-2024 | Cytokines | News

    Anti-GD2-chimeric-antigen-receptor-T-cell-therapy-Sinobioway-Cell-Therapy/prostate-specific-membrane-antigen-CAR-T-cell-therapy-Shanghai-Bioray-Laboratory-Inc

    Cytokine release syndrome
  2. 01-04-2024 | CAR T-Cell Therapy | News

    FDA requires warnings for T-cell cancer after CAR T-cell therapy

  3. 26-04-2024 | Glioma | Online First

    CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas

    Pediatric brain tumors are the primary cause of death in children with cancer. Diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG) are frequently unresectable due to their difficult access location, and 5-year survival remains …

  4. Open Access 01-12-2024 | Lymphoma | Letter

    Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma

    Relapse and toxicity limit the effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL), yet biomarkers that predict outcomes and toxicity are lacking. We examined radiomic features extracted from …

  5. 02-05-2024 | Pancreatic Cancer | Online First

    CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials

    Pancreatic cancer currently ranks as the fourth leading cause of cancer-related deaths in the USA and it is indicated that it is anticipated to reach the second rank in terms of cancer-related mortality by the year 2030 [ 1 ]. Around 60% of …

  6. Open Access 01-06-2024 | Human Papillomavirus | OriginalPaper

    Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy

    Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide, and its incidence continues to rise [ 1 ]. Currently, surgery followed by radiotherapy or concurrent chemoradiotherapy is the treatment of choice for HNSCC [ 1 …

  7. 26-04-2024 | CAR T-Cell Therapy | News | Article

    Is CAR T-cell therapy linked to an increased risk for second primary neoplasms?

    Analysis of FAERS pharmacovigilance data reveals a higher-than-expected incidence of second primary neoplasms in hematologic cancer patients receiving CAR T-cell therapy.

  8. Open Access 01-12-2024 | Solid Tumor | ReviewPaper

    Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

    The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough. Nevertheless, the utilization and effectiveness of CAR-T cell therapy in solid tumors …

  9. Open Access 25-04-2024 | Rituximab | Online First

    Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion

    Despite chimeric antigen receptor (CAR) T-cell therapy has achieved great advances in recent year, approximately 50% of relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL) patients treated with CAR-T experience relapse 6 months …

  10. Open Access 25-04-2024 | Diffuse Large B-Cell Lymphoma | Online First

    Identification of a Patient Suitable for CAR-T Cell Therapy in the Outpatient Setting: A Vodcast and Case Example

    Chimeric antigen receptor T cell (CAR-T) therapies targeting the CD19 antigen have been associated with high and durable response rates in patients with diffuse large B cell lymphoma (DLBCL). CAR-T cell therapies are commonly administered in the …

  11. Open Access 01-06-2024 | Multiple Myeloma | OriginalPaper

    Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma

    In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T cells with a CD8-based transmembrane (TM) and CD137 (41BB) as …

  12. Open Access 04-04-2024 | CAR T-Cell Therapy | Online First

    Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

  13. Open Access 01-12-2024 | Glioblastoma | OriginalPaper

    Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening

    Glioblastoma multiforme (GBM) is the most aggressive and common primary brain tumor, characterized by rapid growth, diffuse infiltration, and poor prognosis. With a median survival period of only 12–15 months and a 5-year survival rate of less …

  14. Open Access 21-03-2024 | Status Epilepticus | Online First

    Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

    Chimeric antigen receptor (CAR) T-cell therapy represents a novel and highly effective treatment for refractory haematological cancers [ 1 , 2 ]. Yet, it is often complicated by systemic and neurological toxicities, namely cytokine release syndrome …

  15. 11-04-2024 | Myasthenia Gravis | Online First

    Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report

  16. Open Access 01-12-2024 | Acute Lymphoblastic Leukemia | ReviewPaper

    Challenges and strategies associated with CAR-T cell therapy in blood malignancies

    Cellular immunotherapy, particularly CAR-T cells, has shown potential in the improvement of outcomes in patients with refractory and recurrent malignancies of the blood. However, achieving sustainable long-term complete remission for blood cancer …

  17. 11-04-2024 | Checkpoint Inhibitors | Online First

    Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study

    Esophageal cancer (EC) ranks as the 8th most frequently diagnosed cancer and the 6th leading cause of cancer-related deaths globally. In China, the majority histological subtype of EC was esophageal squamous cell carcinoma (ESCC), corresponding to …

  18. 20-03-2024 | Acute Kidney Injury | Online First

    Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent, and young adult patients with B-cell acute lymphoblastic leukemia

    CD19-specific chimeric antigen receptor (CAR) T-cell therapy is a highly effective immunotherapy that is increasingly used for the treatment of children, adolescent, and young adult (CAYA) patients with relapsed and/or refractory B-cell acute …

  19. Open Access 01-12-2024 | Photodynamic Therapy | OriginalPaper

    Periodontal ligament stem cell-derived exosome-loaded Emodin mediated antimicrobial photodynamic therapy against cariogenic bacteria

    Dental caries, commonly known as tooth decay, is a multifactorial disease that results from the interaction between various environmental, behavioral, and biological factors [ 1 ]. One of the most important biological factors contributing to dental …

  20. Open Access 23-03-2024 | Cutaneous Squamous Cell Carcinoma | OriginalPaper

    Inconsistent Associations Between Risk Factor Profiles and Adjuvant Radiation Therapy (ART) Treatment in Patients with Cutaneous Squamous Cell Carcinoma and Utility of the 40-Gene Expression Profile to Refine ART Guidance

    National Comprehensive Cancer Network (NCCN) recommendations for follow-up surveillance of patients diagnosed with cutaneous squamous cell carcinoma (cSCC) are different but overlapping for the NCCN-defined Low Risk, High Risk, and Very High Risk …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.